Another ASX biotech in which Karst Peak Capital was invested was Viralytics, which was taken out by Merck in early 2018.
At the time of takeover, Karst Peak Capital was the No. 3 shareholder, holding 4.6% of the company.
Baker Bros. was also a Top 10 shareholder, with 3.9%.
Perhaps worth noting that neither was listed in Top 20 shareholder list in VLA's previous Annual Report. It seems likely an HSBC nominee account was used.
Ann: International institution acquires 14% of Neuren, page-24
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.50 |
Change
0.190(0.98%) |
Mkt cap ! $2.490B | |||
| Open | High | Low | Value | Volume |
| $19.39 | $19.98 | $19.38 | $7.285M | 370.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 7318 | $19.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.52 | 593 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.55 |
Change
0.190 ( 0.83 %) |
||||
| Open | High | Low | Volume | ||
| $19.41 | $19.97 | $19.39 | 83274 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| NEU (ASX) Chart |